McKesson (NYSE:MCK) Stock Price Expected to Rise, Mizuho Analyst Says

McKesson (NYSE:MCK) had its target price raised by analysts at Mizuho from $880.00 to $885.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential upside of 7.98% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Evercore ISI restated an “outperform” rating and issued a $1,000.00 target price on shares of McKesson in a research report on Thursday, November 6th. Robert W. Baird set a $968.00 price objective on McKesson in a report on Wednesday, January 14th. Zacks Research lowered McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Barclays initiated coverage on McKesson in a report on Monday, December 8th. They set an “overweight” rating and a $960.00 price target on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $907.57.

McKesson Price Performance

NYSE:MCK opened at $819.58 on Thursday. The firm has a market capitalization of $101.16 billion, a P/E ratio of 25.51, a P/E/G ratio of 1.40 and a beta of 0.40. The business has a 50 day simple moving average of $825.54 and a 200 day simple moving average of $776.66. McKesson has a 12-month low of $570.51 and a 12-month high of $895.58.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the business posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts anticipate that McKesson will post 32.77 EPS for the current fiscal year.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $861.63, for a total transaction of $283,476.27. Following the completion of the sale, the chief accounting officer directly owned 328 shares in the company, valued at approximately $282,614.64. This trade represents a 50.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On McKesson

A number of hedge funds have recently modified their holdings of the stock. Pinnacle Associates Ltd. raised its position in shares of McKesson by 10.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 2,901 shares of the company’s stock worth $2,379,000 after purchasing an additional 281 shares during the period. Baader Bank Aktiengesellschaft raised its holdings in McKesson by 11.1% during the 4th quarter. Baader Bank Aktiengesellschaft now owns 629 shares of the company’s stock worth $512,000 after buying an additional 63 shares during the period. Allworth Financial LP lifted its stake in McKesson by 1.7% during the fourth quarter. Allworth Financial LP now owns 5,896 shares of the company’s stock valued at $4,836,000 after buying an additional 99 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of McKesson by 4.2% in the fourth quarter. Atria Investments Inc now owns 12,571 shares of the company’s stock worth $10,312,000 after buying an additional 510 shares during the period. Finally, Muhlenkamp & Co. Inc. increased its position in shares of McKesson by 0.3% in the fourth quarter. Muhlenkamp & Co. Inc. now owns 27,193 shares of the company’s stock worth $22,306,000 after acquiring an additional 85 shares in the last quarter. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Raised FY‑2026 adjusted EPS guidance to $38.80–$39.20, citing acceleration in oncology and biopharma services — a direct driver of upside to earnings expectations. McKesson boosts 2026 profit forecast amid specialty drug growth
• Positive Sentiment: Quarterly results showed revenue growth led by specialty distribution and a beat on EPS, supporting the higher guide and investor confidence in the company’s growth mix. McKesson Reports Fiscal 2026 Third Quarter Results
• Neutral Sentiment: Q3 headline numbers: revenue ~ $106.2B (+11.4% YoY) and EPS above consensus (reported ~$9.3 vs. street ~ $9.2) — solid operating performance but not uniformly clean across all metrics. Q3 results summary
• Neutral Sentiment: Strategic move: McKesson has fully exited its European market operations — reduces geographic complexity but narrows diversification and near‑term revenue channels. McKesson fully exits European market
• Negative Sentiment: Operating cash flow weakened materially (reported cash from operations down sharply year‑over‑year), and total liabilities rose — a liquidity and quality‑of‑earnings concern that can temper enthusiasm despite the EPS beat. Earnings: EPS Beats, Profit Growth but Weak Operating Cash Flow
• Negative Sentiment: Notable insider selling (executive sales disclosed) was reported, which can amplify downward pressure or prompt short‑term profit‑taking. Insider trading details

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.